Tempest Therapeutics Announces Data From Phase 1b/2 Study Of Amezalpat (TPST-1120); Shows Six-Month Improvement In Median Overall Survival When Combined With Atezolizumab And Bevacizumab In First-Line Treatment Of Unresectable Or Metastatic Hepatocellular Carcinoma
Portfolio Pulse from Benzinga Newsdesk
Tempest Therapeutics announced positive data from its Phase 1b/2 study of Amezalpat (TPST-1120), showing a six-month improvement in median overall survival when combined with Atezolizumab and Bevacizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma. The company will host a webcast conference call today at 8:30am ET.
June 20, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tempest Therapeutics' Amezalpat (TPST-1120) demonstrated a significant improvement in median overall survival in a Phase 1b/2 study for liver cancer, which could positively impact the stock price.
The significant improvement in median overall survival and the early and persistent separation of survival curves are strong indicators of the drug's efficacy. This positive data is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100